Yiming Data Secures Nearly RMB 100 Million Series B Funding, Serving Over 200 Tier-3 Hospitals and 300+ Departments

Recently, VCBeat learned that Yiming Data, a leading medical big data platform in China, has completed its financing round led byChina State Venture CapitalSecured nearly RMB 100 million in Series B financing, with Zhiyuan Capital serving as the exclusive financial advisor for this round. Following this financing, Yiming will expand its coverage to a broader range of hospitals and departments, providing services to more specialized fields.

Yiming Data is a high-tech enterprise specializing in the field of medical big data, dedicated to providing technologies and services in this domain. With a deep focus on chronic diseases such as cardiovascular, cerebrovascular, and respiratory conditions, Yiming’s automated data acquisition technology—eliminating manual entry—and its advanced capabilities for complex data computation and processing have significantly enhanced the operational efficiency of hospitals and physicians, while unlocking substantial scientific research and academic value.

Yiming’s founder, Ma Min, previously served at major multinational corporations such as Pfizer and Novartis. The company’s partners hail from internet giants like Google and Alibaba. With extensive expertise in healthcare industry experience and resources, data processing, market expansion, and operations, this cross-disciplinary talent ensures a well-balanced team structure.

According to the VCBeat database, YiMing Technology has previously secured two rounds of financing.

On November 2, 2012, Yiming Technology secured tens of millions of RMB in angel-round financing, with investors including Tongdu Capital, Fenghou Capital, Yongbai Capital, and Lianchuang Yongxuan.

On September 30, 2016, Yiming Technology secured tens of millions of RMB in Series A financing, with investors including Tongdu Capital, Western Capital, BlueRun Ventures, Fenghou Capital, and Lianchuang Yongxuan.

Currently, Yiming’s partners include top-tier academic institutions such as the National Health and Family Planning Commission, the National Clinical Research Center for Respiratory Diseases, and the China Cardiovascular Health Alliance. Yiming is also a member of the HL7 China Professional Committee. To date, Yiming has provided professional medical data services to more than 200 Grade A tertiary hospitals and over 300 clinical departments across China.

Currently, Yiming holds three invention patents and several software copyrights. Its advanced technology ensures the integrity, accuracy, timeliness, and continuity of data. The “Yiming Data Acquisition System” replaces traditional manual entry, seamlessly integrates with all hospital systems, and captures comprehensive patient information within the hospital. It can process a single medical record in seconds, achieving fully automated data entry without human intervention. The “Yiming Intelligent Data Processing System” enables data structuring and complex computations. By leveraging data pipelines, rule engines, and natural language understanding (NLU) technologies during the transformation from raw to secondary data, it eliminates systematic errors caused by manual entry by different individuals, achieving industry-leading accuracy. The natural language processing speed of the “Yiming Intelligent Data Processing System” reaches 30,000 records per second, while its neural network-based data cleaning capability processes up to 100,000 records per second with an accuracy rate of 97%.

Notably, Yiming has recently joined Microsoft Research Asia, becoming the sole Chinese medical big data company partnered with Microsoft, having been selected through a highly competitive process with an acceptance rate of just 0.2%. This collaboration will undoubtedly enable the delivery of more valuable services to clients in clinical decision support systems and AI-driven solutions, while achieving greater precision in data mining.

The investing institution in this round, Shenzhen Guozhong Venture Capital Management Co., Ltd., is a professional venture capital firm entrusted with managing the first physical fund of the National Small and Medium-sized Enterprise (SME) Development Fund—the SME Development Fund (Shenzhen Limited Partnership). Its primary investment focus includes strategic emerging industries such as information technology, internet/new media, biopharmaceuticals/modern agriculture, new energy/energy conservation and environmental protection, chemicals/new materials, high-end equipment manufacturing, and consumer goods/modern services.